These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32466781)

  • 1. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
    Ryan ST; Zhang J; Burner DN; Liss M; Pittman E; Muldong M; Shabaik A; Woo J; Basler N; Cunha J; Shalapour S; Estrada MV; Karin M; Messer K; Howell S; Kane CJ; Jamieson CAM
    J Transl Med; 2020 May; 18(1):214. PubMed ID: 32466781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor infiltrating B-cells are increased in prostate cancer tissue.
    Woo JR; Liss MA; Muldong MT; Palazzi K; Strasner A; Ammirante M; Varki N; Shabaik A; Howell S; Kane CJ; Karin M; Jamieson CA
    J Transl Med; 2014 Jan; 12():30. PubMed ID: 24475900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression and CD8
    Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
    Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
    Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
    Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
    Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
    Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
    Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
    Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    Kumar T; Hobbs E; Yang F; Chang JT; Contreras A; Cuentas ERP; Garber H; Lee S; Lu Y; Scoggins ME; Adrada BE; Whitman GJ; Arun BK; Mittendorf EA; Litton JK
    Clin Cancer Res; 2022 Sep; 28(17):3669-3676. PubMed ID: 35736816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
    Bergstrom CP; Ruffell B; Ho CM; Higano CS; Ellis WJ; Garzotto M; Beer TM; Graff JN
    Anticancer Drugs; 2017 Jan; 28(1):120-126. PubMed ID: 27669423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
    Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
    Baas W; Gershburg S; Dynda D; Delfino K; Robinson K; Nie D; Yearley JH; Alanee S
    Clin Genitourin Cancer; 2017 Oct; 15(5):577-581. PubMed ID: 28461179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 19. ELAVL1 regulates PD-L1 mRNA stability to disrupt the infiltration of CD4-positive T cells in prostate cancer.
    Cai Z; Zhai X; Xu J; Hong T; Yang K; Min S; Du J; Cai Z; Wang Z; Shen M; Wang D; Shen Y
    Neoplasia; 2024 Nov; 57():101049. PubMed ID: 39265220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
    Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
    J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.